Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing’s Syndrome

Table 1

Biochemistry evaluations during treatment with mifepristone.

Test (normal range)	Baseline (before MIFE)	Week 6	Week 10	Week 16	Week 24	2-week follow-up (off MIFE)
ACTH, pg/mL; (7–50 pg/mL)	345	279	188	250	304	652
UFC, mcg/24 h; (2.0–42.4 mcg/24 h)	2250	1536	104	122	434	4716
Serum cortisol, mcg/dL; (8 AM, 4.0–22.0 mcg/dL)	46	41	31	31	37	68
Late-night salivary cortisol, mcg/dL; (10 PM-11 PM, ≤0.09 mcg/dL)	1.71	2.18	0.56	0.73	1.49	4.91

Patient continued to receive octreotide LAR 30 mg every month throughout the study. ACTH denotes adrenocorticotropin hormone, LAR long-acting release, MIFE mifepristone, and UFC urinary-free cortisol. To convert the values for UFC to nanomoles per 24 h, multiply by 2.76. To convert the values for ACTH to picomoles per liter, multiply by 0.22. To convert the values for serum cortisol and late-night salivary cortisol to nanomoles per liter, multiply by 27.6.